BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36992824)

  • 21. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
    Li J; Yang S; Li Y; Li C; Xia Y; Zhu S; Xia J
    Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1295-1303. PubMed ID: 35835873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Sheng Y; Wang Q; Liu HF; Chen WH; He ZM; Wang Q
    Acad Radiol; 2023 Jul; 30(7):1288-1297. PubMed ID: 36424310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel nomogram based on the nutritional risk screening 2002 score to predict survival in hepatocellular carcinoma treated with transarterial chemoembolization.
    Chen X
    Nutr Hosp; 2022 Aug; 39(4):835-842. PubMed ID: 35916127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study.
    Hsu CY; Liu PH; Hsia CY; Lee YH; Nagaria TS; Lee RC; Lin HC; Huo TI
    Ann Surg Oncol; 2016 Mar; 23(3):994-1002. PubMed ID: 26487000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
    Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
    BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
    Qi X; Liu L; Wang D; Li H; Su C; Guo X
    Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
    Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
    J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: a preliminary retrospective study.
    Yang S; Zhang Z; Su T; Yu J; Cao S; Wang H; Jin L
    Eur J Med Res; 2022 Jul; 27(1):131. PubMed ID: 35879734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Nomogram for Hepatitis B Virus-related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection.
    Huang J; Liu FC; Li L; Yuan SX; Yang Y; Jiang BG; Liu H; Pan ZY
    Am J Clin Oncol; 2020 Jan; 43(1):20-27. PubMed ID: 31633514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
    Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
    Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.
    Xu JX; Qin SL; Wei HW; Chen YY; Peng YC; Qi LN
    Ann Med; 2023 Dec; 55(1):2199219. PubMed ID: 37070467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.
    Zhang JX; Yan HT; Ding Y; Liu J; Liu S; Zu QQ; Shi HB
    Ann Med; 2022 Dec; 54(1):1562-1569. PubMed ID: 35639492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
    Cheng S; Hu G; Jin Z; Wang Z; Xue H
    Eur Radiol; 2023 Dec; 33(12):8715-8726. PubMed ID: 37436507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
    Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
    BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.